Risk Factors for Bleeding during Anticoagulation

Petersen P. Goysen G. Godtfredsen J. Andersen E D Andersen B. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. Lancet 1989: i: 175–79.

Stroke Prevention in Atrial Fibrillation Study Group Investigators. Stroke prevention in atrial fibrillation study: Final results. Circulation 1991; 84: 527–39.

The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med 1990; 323: 1505–11.

Connolly S J Laupacis A. Gent M. . Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. J Am Coll Cardiol 1991; 18: 349–55.

Ezekowitz M D Bridgers S L James K E . Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. N Engl J Med 1992; 327: 1406–12.

EAFT (European Atrial Fibrillation Trial) Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 1993; 342: 1255–62.

Smith P. Arnesen H. Holme I. The effect of warfarin on mortality and reinfarction after myocardial infarction. N Engl J Med 1990; 323: 147–52.

Fernandez F. Nguyen P. Van Ryn J. . Hemorrhagic doses of heparin and other glycosaminoglycans induce a platelet defect. Thromb Res 1986; 43: 491–95.

Blajchman M A Young E. Ofosu F. A. Effects of unfractionated heparin, dermatan sulfate and low molecular weight heparin on vessel wall permeability in rabbits. Ann N Y Acad Sci 1989; 556: 245–53.

Salzman E W Deykin D. Shapiro R M Rosenberg R. Management of heparin therapy: Controlled prospective trial. N Engl J Med 1975; 292: 1046–50.

Glazier R I Crowell E. B. Randomised prospective trial of continuous vs intermittent heparin therapy. JAMA 1976; 236: 1365–67.

Landefeld C S Beyth R. J. Anticoagulant-related bleeding; clinical epidemiology, prediction and prevention. Am J Med 1993; 95: 315–28.

Collins R. Scrimgeour A. Yusuf S. Peto R. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin: Overview of results of randomised trials in general, orthopaedic, and urologic surgery. N Engl J Med 1988; 318: 1162–73.

Green D. Lee M Y Ito V Y . Fixed vs adjusted-dose heparin in the prophlaxis of thromboembolism in spinal cord injury. JAMA 1988; 260: 1255–58.

Levine M N Hirsh J. Kelton J. G. Heparin-induced bleeding. In: Lane D A Lindahl U. eds. Heparin: Chemical and biological properties clinical applications. London: Edward Arnold, 1989: 517–32.

Norman C S Provan J. L. Control and complications of intermittent heparin therapy. Surg Gynecol Obstet 1977; 145: 338–42.

Landefeld S. Flatley M. Weisberg M. Cook E F Goldman L. Identification and preliminary validation of predictors of major bleeding in hospitalised patients starting anticoagulant therapy. Am J Med 1987; 82: 703–13.

Basu D. Gallus A. Hirsh J. Cade J. A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time. N Engl J Med 1972; 287: 324–27.

Pitney W R Pettit J E Armstrong L. Control of heparin therapy. Br Med J 1970; 4: 139–41.

Mant M J O'Brien B D Thong K L Hammond G W Birtwhistle R V Grace M. G. Haemorrhagic complications of heparin therapy. Lancet 1977; i: 1133–35.

Wilson J R Lampman J. Heparin therapy: A randomised prospective study. Am Heart J 1979; 97: 155–58.

Fagher B. Lundh B. Heparin treatment of deep vein thrombosis: Effects and complications after continuous or intermittent heparin administration. Acta Med Scand 1981; 210: 357–61.

Wilson J E Bynum L J Parkey R. W. Heparin therapy in venous thromboembolism. Am J Med 1981; 70: 808–16.

Hirsh J. Heparin. N Engl J Med 1991; 324: 1565–74.

Bentley P G Kakkar V V Scully M F . An objective study of alternative methods of heparin administration. Thromb Res 1980; 18: 177–87.

Walker M G Shaw J W Thomson G J Cumming J G Thomas M. L. Subcutaneous calcium heparin versus intravenous sodium heparin in treatment of established acute deep vein thrombosis of the legs: A multicentre prospective randomised trial. Br Med J 1987; 294: 1189–92.

Hull R D Raskob G E Hirsh J. . Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. N Engl J Med 1986; 315: 1109–14.

Doyle D J Turpie A G G Hirsh J. . Adjusted subcutaneous heparin or continuous intravenous heparin in patients with acute deep vein thrombosis. Ann Intern Med 1987; 107: 441–45.

Lopacuik S. Meissner A J Ciesielski L. Korzycki J. Subcutaneous sodium heparin versus intravenous sodium heparin in the treatment of deep vein thrombosis. Proceedings of the 6th International Meeting of the Danubian League Against Thrombosis and Haemorrhagic Disorders, Vienna, Austria, 30 May–3 June 1989: 389–93.

Pini M. Pattacini C. Quintavalla R. . Subcutaneous vs intravenous heparin in the treatment of deep vein thrombosis. A randomised clinical trial. Thromb Haemost 1990; 64: 222–26.

Hommes D W Bura A. Mazzolai L. Büller H R Ten Cate J. W. Subcutaneous heparin compared with continuous intravenous heparin administration in the initial treatment of deep vein thrombosis: A metaanalysis. Ann Intern Med 1992; 116: 279–84.

Leizorovicz A. Haugh M C Chapuis F-R Samama M M Boissel J-P. Low molecular weight heparin in prevention of perioperative thrombosis. BMJ 1992; 305: 913–20.

Turpie A G G Hirsh J. Jay R M . Double-blind randomised trial of ORG10172 low molecular-weight heparinoid in the prevention of deep-vein thrombosis in thrombotic stroke. Lancet 1987; i: 523–26.

Turpie A G G Levine M N Hirsh J. . A randomised controlled trial of a low molecular weight heparin (enoxaparin) to prevent deep vein thrombosis in patients undergoing elective hip surgery. N Engl J Med 1986; 315: 925–29.

Walker A M Jick H. Prediction of bleeding during heparin therapy. JAMA 1980; 244: 1209–12.

Jick H. Slone D. Borda I T Shapiro S. Efficacy and toxicity of heparin in relation to age and sex. N Engl J Med 1968; 279: 284–86.

Vieweg W V R Piscatelli R L Houser J J Proulx R. A. Complications of intravenous administration of heparin in elderly women. JAMA 1970; 213: 1303–306.

Hull R D Raskob G E Rosenbloom D. . Heparin for five days as compared with ten days in the initial treatment of proximal venous thrombosis. N Eng J Med 1982; 307: 1676–81.

Landefeld C S Goldman L. Major bleeding in outpatients treated with warfarin: Incidence and prediction by factors known at the start of outpatient therapy. Am J Med 1989; 87: 144–52.

Diamond T. Gray W J Chee C P Fannin T. F. Subdural haematoma associated with long term oral anticoagulation. Br J Neurosurg 1988; 2: 351–56.

Kase C S Robinson R K Stein R W . Anticoagulant-related intracerebral haemorrhage. Neurology 1985; 35: 943–48.

Wintzen A R De Jonge H. Loeliger E A Bots G. T. A. M. The risk of intracerebral haemorrhage during anticoagulant treatment: A population study. Am J Neurol 1984; 16: 553–58.

Mattle H. Kohler S. Huber P. Rohner M. Steinsiepe K. F. Anticoagulation-related intracranial extracerebral haemorrhage. J Neurol Neurosurg Psychiatry 1989; 52: 829–37.

Franke C L De Jonge J. Van Swieten J C de Coul Op A A W Van Gijin J. Intracerebral haematomas during anticoagulant treatment. Stroke 1990; 21: 726–30.

Turpie A G G Bloch R. Duke R. Heparin in the treatment of thromboembolic stroke. Ann N Y Acad Sci 1989; 556: 406–15.

Sethi G K Copeland J G Goldman S. . Implications of preoperative administration of aspirin in patients undergoing coronary artery bypass grafting. J Am Coll Cardiol 1990; 15: 15–20.

The SCATI Group. Randomized controlled trial of subcutaneous calcium heparin in acute myocardial infarction. Lancet 1989; ii: 182–85.

Gruppo Italian per lo Studio della Sopravivenza nell'Infarto Miocardio. GISSI-2. A factorial randomized trial of alteplase versus streptokinase and heparin versus no heparin among 12 490 patients with acute myocardial infarction. Lancet 1990; ii: 65–70.

The International Study Group. In-hospital mortality and clinical course of 20 891 patients with suspected myocardial infarction randomized between alteplase and streptokinase with or without heparin. Lancet 1990; ii: 71–75.

Hirsh J. Deykin D. Poller L. ‘Therapeutic range’ for oral anticoagulant therapy. Chest 1986; 89: 11S–15S.

Hirsh J. Poller L. Deykin D. Levine M. Dalen J. E. Optimal therapeutic range for oral anticoagulant therapy. Chest 1989; 95 (suppl): 5S–11S.

Levine M N Raskob G. Hirsh J. Hemorrhagic complications of long-term anticoagulant therapy. Chest 1989; 95 (suppl): 26S–36S.

Levine M N Hirsh J. Landefeld S. Raskob G. Hemorrhagic complications of anticoagulant treatment. Chest 1992; 102 (suppl): 352S–63S.

Hull R. Hirsh J. Jay R. . Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis. N Engl J Med 1982; 307: 1676–81.

Turpie A G G Gunstensen J. Hirsh J. Nelson H. Gent M. Randomised comparison of two intensities of oral anticoagulant therapy after tissue heart valve replacement. Lancet 1988; i: 1242–45.

Saour J N Sieck J O Mamo L A R Gailus A. S. Trial of different intensities of anticoagulation in patients with prosthetic heart valves. N Engl J Med 1990; 322: 428–32.

Altman R. Rouvier J. Gurfinkel E. Comparison of two levels of anticoagulant therapy in patients with substitute heart valves. J Thorac Cardiovasc Surg 1991; 101: 427–31.

Forfar J. C. A 7 year analysis of haemorrhage in patients in long-term anticoagulant treatment. Br Heart J 1979; 42: 128–32.

Lundstrom T. Ryden L. Haemorrhagic and thromboembolic complications in patients with atrial fibrillation on anticoagulant prophylaxis. J Intern Med 1989; 225: 137–42.

Petitti D B Strom B L Melmon K. L. Prothrombin time ratio and other factors associated with bleeding in patients treated with warfarin. J Clin Epidemiol 1989; 42: 759–64.

Coon W W Willis P W III . Hemorrhagic complications of anticoagulant therapy. Arch Intern Med 1974; 133: 386–92.

Landefeld C S Rosenblatt M W Goldman L. Bleeding in outpatients treated with warfarin: Relation to the prothrombin time and important remediable lesions. Am J Med 1989; 87: 153–59.

Jaffin B W Bliss C M Lamont J. T. Significance of occult gastrointestinal bleeding during anticoagulation therapy. Am J Med 1987; 83: 269–72.

Wilcox C M Truss C. D. Gastrointestinal bleeding in patients receiving long term anticoagulant therapy. Am J Med 1988; 84: 683–90.

Tabibian N. Acute gastrointestinal bleeding in anticoagulated patients: A prospective evaluation. Am J Gastroenterol 1989; 84: 10–12.

Choudari C P Rajgopal C. Palmer K. R. Acute gastrointestinal haemorrhage in anticoagulated patents: Diagnoses and response to endoscopic treatment. Gut 1994; 35: 464–66.

McInnes G T Helenglass G. The performance of clinics for outpatient control of anticoagulation. J R Coll Physicians Lond 1989; 21: 42–45.

Gurwitz J H Goldberg R J Holden A. Knapic N. Ansell J. Age-related risks of long-term oral anticoagulant therapy. Arch Intern Med 1988; 148: 1733–36.

Altman R. Boullon F. Rouvier J. Raca R. De la Fuente L. Favaloro R. Aspirin and prophylaxis of thromboembolic complications in patients with substitute heart valves. J Thorac Cardiovasc Surg 1976; 72: 127–29.

Chesebro J K Fuster V. Elveback L R . Trial of combined warfarin plus dipyidamole or aspirin therapy in prosthetic heart valve replacement: Danger of aspirin compared with dipyridamole. Am J Cardiol 1983; 51: 1537–41.

Dale J. Myhre E. Loew D. Bleeding during acetylsalicylic acid and anticoagulant therapy in patients with reduced platelet reactivity after aortic valve replacement. Am Heart J 1980; 99: 746–51.

Turpie A G G Gent M. Laupacis A. . A comparison of aspirin with placebo in patients treated with warfarin after heart-valve replacement. N Engl J Med 1993; 329: 524–29.

Landefeld C S McGuire E. Rosenblatt M. W. A bleeding risk index for estimating the probability of major bleeding in hospitalized patients starting anticoagulant therapy. Am J Med 1990; 89: 569–78.

Landefeld C S Anderson P. A. Guideline-based consultation to prevent anticoagulant-related bleeding: A randomized, controlled trial in a teaching hospital. Ann Intern Med 1992; 116: 829–37.

White R H McCurdy S A Von Marensdorff H. Woodruff D E Jr Leftgoff L. Home prothrombin time monitoring after the initiation of warfarin therapy: A randomised prospective study. Ann Intern Med 1989; 111: 730–37.

Ansell J. Holden A. Knapic N. Patient self-management of oral anticoagulation guided by capillary (fingerstick) whole blood prothrombin times. Arch Intern Med 1989; 149: 2509–11.

Furie B. Diuguid C F Jacobs M. Diuguid D L Furie B. C. Randomised prospective trial comparing the native prothrombin antigen with the prothrombin time for monitoring oral anticoagulant therapy. Blood 1990; 75: 344–49.